Spyre Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SYRE in the last 7 days.
BTIG reiterated a Buy rating on Spyre Therapeutics with a $121 price target, implying a 51.4% upside from the Oct 16 close. The firm cited positive Phase 2b data for tulisokibart and a strong pipeline in immune-mediated diseases.
Spyre Therapeutics (SYRE), a biotech company with a $7.5B market cap, saw its stock drop 15% from recent highs. The company raised $350M in a secondary offering, leaving it with $1.4B in cash. SYRE's antibodies for ulcerative colitis and IBD showed promising results in clinical trials, with a potential global market of $40B by 2030. Analysts project $5B in revenue by 2034, and the stock is below most price targets.
Spyre Therapeutics (NASDAQ:SYRE) presented clinical data on three IBD antibody therapies (SPY001, SPY002, SPY003) at UEGW 2026, showing proof-of-concept. The SKYLINE study tests these therapies as monotherapies and combinations. Silvio Danese, SKYLINE trial chair, expressed excitement for future combination results.
Recent SYRE coverage spans financial news, corporate actions and market movers.
In the last 30 days, SYRE insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($6.3M). The most active reporter was Turtle Cameron, Chief Executive Officer, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
BTIG reiterated a Buy rating on Spyre Therapeutics with a $121 price target, implying a 51.4% upside from the Oct 16 close. The firm cited positive Phase 2b data for tulisokibart and a strong pipeline in immune-mediated diseases.
Positive trial data may boost investor sentiment and support a price rebound.
Positive Phase 2 data could lift SYRE as investors reassess the pipeline's commercial potential.
Positive Phase II data may boost investor confidence and drive the stock higher.
Analyst initiation with a high target may provide near-term support, but the article flags valuation risk and recent insider selling.
AlphAI scores every news story that mentions SYRE with an AI model for sentiment and relevance, and aggregates insider trades from Spyre Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG reiterated a Buy rating on Spyre Therapeutics with a $121 price target, implying a 51.4% upside from the Oct 16 close. The firm cited positive Phase 2b data for tulisokibart and a strong pipeline in immune-mediated diseases.
1 min readSpyre Therapeutics (SYRE), a biotech company with a $7.5B market cap, saw its stock drop 15% from recent highs. The company raised $350M in a secondary offering, leaving it with $1.4B in cash. SYRE's antibodies for ulcerative colitis and IBD showed promising results in clinical trials, with a potential global market of $40B by 2030. Analysts project $5B in revenue by 2034, and the stock is below most price targets.
3 min readSpyre Therapeutics (NASDAQ:SYRE) presented clinical data on three IBD antibody therapies (SPY001, SPY002, SPY003) at UEGW 2026, showing proof-of-concept. The SKYLINE study tests these therapies as monotherapies and combinations. Silvio Danese, SKYLINE trial chair, expressed excitement for future combination results.
2 min readJefferies named Spyre Therapeutics its top pick in small- to mid-cap biotech, citing its pipeline of combination therapies for inflammatory bowel disease. The company's three treatments are expected to report Phase 2 data in 2027. Jefferies highlighted encouraging efficacy signals and favorable safety profiles, with real-world data showing high remission rates.
2 min readUBS initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a $120.00 price target, indicating potential growth. The company has a $7.94B market cap, a P/S ratio of 49.12, and a GF Score of 32/100, showing below-average performance in key metrics. Insiders have sold $16.9M in shares over the last three months.
5 min readSpyre Therapeutics' stock rose 4.4% in morning trading, recovering from a selldown after a $350M public offering priced at $85 per share. Jefferies highlighted Syros Pharmaceuticals as a top biotech pick for 2027, citing positive data on combination therapies for inflammatory bowel diseases. The broader market also gained, with the S&P 500, Dow Jones, and Nasdaq posting modest increases.
2 min readSpyre Therapeutics (SYRE) completed a $350M equity offering at $85 per share, adding 4.1M shares. The stock has declined 9.2% in 7 days, 9.1% in 30 days, and 18.1% in 90 days, despite a 164.4% YTD return. Analysts see a fair value of $120.08, citing its antibody pipeline and long cash runway. The company's future depends on clinical trial results and market sentiment.
2 min readSpyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On October 5, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company
2 min readSpyre Therapeutics (Nasdaq: SYRE) priced a $350M public offering of 4.1M shares at $85 each, with an option for $52.5M more. Proceeds will fund clinical trials, manufacturing, and R&D. The offering is expected to close Oct 7, 2026.
2 min readSpyre Therapeutics' CLO, Heidy King-Jones, sold 28,933 shares for $2.63M and exercised options for 28,933 shares at $14.50 each. The stock has risen 487% in a year but is deemed overvalued. Spyre's market cap is $7.93B. Recent Phase II trial results showed mixed efficacy for its rheumatoid arthritis treatment, with analysts maintaining Buy/Outperform ratings and price targets between $110 and $130.
2 min read
